Hungarian researchers develop mRNA approach to turn cold tumors into hot ones

At the SZBK Genetic and Biochemical Institutes in Szeged, a team is engineering a novel immunotherapy that uses nucleoside-modified mRNA packaged in lipid nanoparticles to deliver a metabolic regulator protein to patients. The temporary expression of this protein is expected to disrupt the immunosuppressive environment created by cold tumors, effectively converting them into hot tumors that the immune system can attack.

This approach builds on the same delivery technology employed in mRNA vaccines but applies it to cancer treatment, potentially enabling scalable, pre-manufactured therapies. By targeting tumor metabolism, the researchers aim to enhance the efficacy of existing immunotherapeutic regimens. Early laboratory results suggest the concept could open a pathway to combined mRNA-based cancer therapies. The work is still in pre-clinical stages, with further testing required before clinical trials.